The Study of a Novel Sorafenib Derivative HLC-080 as an Antitumor Agent

In this study, our objective is to evaluate the potential of a novel Sorafenib derivative, named HLC-080, as a new anticancer agent for colon cancer. We firstly carried out MTT assay, colony formation assay, flow cytometry analysis and transwell invasion assay to determine effect of our compound HLC...

Descripción completa

Detalles Bibliográficos
Autores principales: Tang, Ke, Luo, Can, Li, Yan, Lu, Chenshu, Zhou, Wanqi, Huang, Haihong, Chen, Xiaoguang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2014
Materias:
Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086976/
https://www.ncbi.nlm.nih.gov/pubmed/25004130
http://dx.doi.org/10.1371/journal.pone.0101889

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4086976/
https://www.ncbi.nlm.nih.gov/pubmed/25004130
http://dx.doi.org/10.1371/journal.pone.0101889

Ejemplares similares